Karol M. Córdoba

High Prevalence of Insulin Resistance in Asymptomatic Patients with Acute Intermittent Porphyria and Liver-Targeted Insulin as a Novel Therapeutic Approach

Isabel Solares, Laura Izquierdo‐Sánchez, Montserrat Morales‐Conejo et al. · Biomedicines · 2021 · 22 citations · Full text

Medicine, Biochemistry, Endocrinology +17

mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks

Daniel Jericó, Karol M. Córdoba, Lei Jiang et al. · Molecular Therapy — Nucleic Acids · 2021 · 20 citations · Full text

Life Sciences, Biochemistry, Pharmacology +15

Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria

Karol M. Córdoba, Irantzu Serrano-Mendioroz, Daniel Jericó et al. · Science Translational Medicine · 2022 · 16 citations · Full text

Medicine, Neuroscience, Pharmacology +14

Heme oxygenase-1 inducer hemin does not inhibit SARS-CoV-2 virus infection

Sheila Maestro, Karol M. Córdoba, Cristina Olagüe et al. · Biomedicine & Pharmacotherapy · 2021 · 13 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +16

Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

Karol M. Córdoba, Daniel Jericó, Lei Jiang et al. · Gut · 2024 · 10 citations · Full text

Life Sciences, Neuroscience, Pharmacology +16